New effects of chondroitin sulfate December 7th 2007, in ft. Lauderdale.
Barcelona, Spain (PRWEB) December 5, 2007 -- In conjunction with the OARSI (Osteoarthritis Research Society International) 12th World Congress, Bioiberica will be hosting a satellite breakfast symposium on Friday, December 7th, 2007 at 7:00 am - 8:30 am at (venue) Ft.Lauderdale, Florida.
The breakfast program will be chaired by Course Director Patrick du Souich, M.D., PhD., an eminent expert in the treatment of Osteoarthritis. Dr du Souich is the Professor and Director, Department of Pharmacology Faculty of Medicine, University of Montreal, Quebec, Canada.
The symposium will cover six topics of interest in the diognosis and treatment of Osteoarthritis and Synovitis including:
- Pathophysiology of Osteoarthritis and Synovitis
- Ultrasonography as a technique to diagnose and monitor synovitis in patients with osteoarthritis
- Quantification of OA cartilage and synovial structural changes by MRI: Novel technologies
- Anti-inflammatory activity of chondroitin sulfate
- Clinical Review of Chondroitin Sulfate in Osteoarthritis
- The effect of chondroitin sulfate on synovitis / joint effusion. Data from the Glucosamine and Chondroitin Arthritis Intervention Trial (GAIT)
Synovitis is an inflammatory process of the synovial membrane, which is a tissue that lines the cavities of joints, tendon sheets and bursae and makes synovial fluid, which has a lubricating function. Targeted inhibition of synovitis in early OA may limit the rates of progressive cartilage degradation and functional impairment. The nutritional supplement chondroitin sulfate (CS) may prove to be a suitable add-on or alternative to various anti-inflammatory drugs in the treatment of synovitis as shown by the results of a recent NIH-clinical trial published in The New England Journal of Medicine (NEJM). In this study, patients administered with 1200 mg daily of CS, experienced significant improvement in joint swelling and joint effusion (signs of synovitis) compared to the group of patients receiving no treatment.
Distinguished speakers will review the latest clinical advances and innovative imaging modalities to treat patients with synovitis and osteoarthritis (OA), and there will be two Q & A sessions encouraging lively debate.
Members of the press and medical professionals wanting to learn more about the role of chondroitin and glucosamine as clinically effective treatment options for OA and synovitis should attend. The symposium is free to registered attendees.
Among CS ingredients available in the marketplace, CS b™ Bio-Active, developed by the Spanish company, Bioiberica, has been used in more published studies than any other brand. It was featured in the groundbreaking GAIT (Glucosamine/Chondroitin Arthritis Intervention) study and can be found in exclusivity in Cosamin DS in USA. Since the early 1980s, CS b™ Bio-Active has helped more than 15 million people worldwide relieve the symptoms of OA.
Bioiberica has become a recognized leader in joint health. Established in 1975, the company has pioneered advancements in pharmaceuticals and dietary supplements that have led to the development of a global business in over 40 countries around the world. Dedicated to research, Bioiberica has established itself as on of the most prestigious names in the industry for top-quality raw materials that are backed by science.
For more information on the science supporting the use of CS, visit www.csbioactive.com.
To arrange an interview with a company spokesperson or a member of the medical advisory panel, please contact Tamara York at ADinfinitum, 212.693.2150, Ext 314 or email at tamara @ adinfinitumny.com.
###
Trackback URL: http://www.prweb.com/pingpr.php/UGlnZy1Qcm9mLUNvdXAtU3VtbS1UaGlyLVplcm8=
|
